Current advances and challenges in HIV-1 vaccines

被引：12

作者：

Rodriguez-Chavez I.R. ^{[1
]}

Allen M. ^{[1
]}

Hill E.L. ^{[1
]}

Sheets R.L. ^{[1
]}

Pensiero M. ^{[1
]}

Bradac J.A. ^{[1
]}

D'Souza M.P. ^{[1
]}

机构：

[1] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

来源：

Current HIV/AIDS Reports | 2006年 / 3卷 / 1期

关键词：

Venezuelan Equine Encephalitis Virus; Vaccine Research Center;

D O I：

10.1007/s11904-006-0007-0

中图分类号：

学科分类号：

摘要：

Recent advances in science, which have aided HIV-1 vaccine development, include an improved understanding of HIV-1 envelope structure and function, expansion of the pipeline with innovative vaccine strategies, promising multi-gene and multi-clade vaccines that elicit cellular immunity, conduct of clinical trials in a global network, and development of validated techniques that enable simultaneous measurement of multiple T cell vaccine-induced immune responses in humans. A common feature of several preventive vaccine strategies now in early clinical trials is their ability in nonhuman primates to attenuate clinical disease rather than completely prevent HIV-1 infection. One vaccine concept has been tested in large-scale clinical trials, two are currently in efficacy trials, and one more is poised to enter efficacy trial in the next few years. Simultaneously, expanded efforts continue to identify new designs that induce mucosal immunity as well as broadly neutralizing antibodies. Copyright © 2006 by Current Science Inc.

引用

页码：39 / 47

页数：8

共 50 条

[1]

Kwong P.D., Wyatt R., Robinson J., Et al., Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody, Nature, 393, pp. 648-659, (1998)

[2]

Wei X., Decker J.M., Wang S., Et al., Antibody neutralization and escape by HIV-1, Nature, 422, pp. 307-312, (2003)

[3]

Myszka D.G., Sweet R.W., Hensley P., Et al., Energetics of the HIV gp120-CD4 binding reaction, Proc Natl Acad Sci U S A, 97, pp. 9026-9031, (2000)

[4]

Kwong P.D., Doyle M.L., Casper D.J., Et al., HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites, Nature, 420, pp. 678-682, (2002)

[5]

Preston B.D., Reverse transcriptase fidelity and HIV-1 variation, Science, 275, pp. 228-229, (1997)

[6]

Binley J.M., Wrin T., Korber B., Et al., Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies, J Virol, 78, pp. 13232-13252, (2004)

[7]

Trkola A., Kuster H., Rusert P., Et al., Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies, Nat Med, 11, pp. 615-622, (2005)

[8]

Haynes B.F., Fleming J., St. Clair E.W., Et al., Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies, Science, 308, pp. 1906-1908, (2005)

[9]

Rawal B.D., Degula A., Lebedeva L., Et al., Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection, J Acquir Immune Defic Syndr, 33, pp. 349-355, (2003)

[10]

Sanigadharan M.G., Popovic M., Bruch L., Et al., Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS, Science, 224, pp. 506-508, (1984)

← 1 2 3 4 5 →